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The dogma that life without insulin is incompatible
has recently been challenged by results showing
the viability of insulin-deficient rodents undergoing
leptin monotherapy. Yet, the mechanisms underlying
these actions of leptin are unknown. Here, the meta-
bolic outcomes of intracerebroventricular (i.c.v.)
administration of leptin in mice devoid of insulin
and lacking or re-expressing leptin receptors
(LEPRs) only in selected neuronal groups were
assessed. Our results demonstrate that concomitant
re-expression of LEPRs only in hypothalamic
g-aminobutyric acid (GABA) and pro-opiomelano-
cortin (POMC) neurons is sufficient to fully mediate
the lifesaving and antidiabetic actions of leptin in in-
sulin deficiency. Our analyses indicate that enhanced
glucose uptake by brown adipose tissue and soleus
muscle, as well as improved hepatic metabolism,
underlies these effects of leptin. Collectively, our
data elucidate a hypothalamic-dependent pathway
enabling life without insulin and hence pave the
way for developing better treatments for diseases
of insulin deficiency.
INTRODUCTION
Insulin deficiency is caused by (i) autoimmune-mediated
destruction of pancreatic b cells (as seen in type 1 diabetes
mellitus [T1DM]) and (ii) metabolic-stress-induced pancreatic b
cell dysfunction and death, dedifferentiation (as seen in agingCell Meand type 2 diabetes mellitus [T2DM]), or complete pancreatec-
tomy (Butler et al., 2007; Coppari and Bjørbæk, 2012; Talchai
et al., 2012). If untreated, this defect leads to hyperglycemia,
polyuria, ketoacidosis, and death. To date, insulin therapy is
the only lifesaving intervention available to several millions of
people suffering from insulin deficiency. Thus, daily insulin
administrations and frequent glucose monitoring are quotidian
activities of these patients. Despite the undisputable fact that
therapeutic insulin has converted a previously lethal defect into
a life-compatible malady, this approach does not restore meta-
bolic homeostasis and may even cause serious unwanted
effects. For example, probably owing to the established lipo-
genic actions of the hormone (Horton et al., 2002), long-term
insulin treatment is suspected to underlie the excessive ectopic
lipid deposition (i.e., in nonadipose tissues) and the extremely
high incidence of coronary artery disease observed in diabetic
subjects (Larsen et al., 2002; Orchard et al., 2003). It is likely
that these lipogenic actions of insulin promote a vicious cycle
of lipid-induced insulin resistance in liver and skeletal muscle
and hence lead to an increased insulin requirement in the long-
term management of diabetes (Shulman, 2000). Furthermore,
due to the potent and fast-acting glycemia-lowering effects of
insulin, intensive insulin therapy significantly increases the risk
of hypoglycemia (an event that is disabling and can even be fatal)
(Cryer, 2009). Thus, better therapies for the treatment of dis-
eases characterized by insulin deficiency are needed.
A major barrier to the development of superior treatments has
been the dogma that life without insulin is not possible. However,
while insulin appears to be an absolute requirement for normal
organismal development, the idea that insulin is also indispens-
able for survival in adulthood needs to be revised. Indeed, we
and others have shown that leptin monotherapy reverses several
metabolic aberrancies and permits survival of adult rodents
rendered insulin deficient. Notably, leptin therapy in this contexttabolism 18, 431–444, September 3, 2013 ª2013 Elsevier Inc. 431
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Figure 1. i.c.v. Leptin Administration Reverses Lethality and Improves Hyperglycemia Caused by Complete Insulin Deficiency
(A) Experimental design using RIP-DTRmice (Thorel et al., 2010). Leptin (25 ng/hr) or placebo (PBS) was intracerebroventricularly (i.c.v.) administered starting at
day 0 in DT-i.c.v.-leptin or DT-i.c.v.-placebomice, respectively. DT-i.c.v.-leptin and DT-i.c.v.-placebomice were rendered insulin deficient by intraperitoneal (i.p.)
diphtheria toxin (DT) administration at days 0, 3, and 5. Age-matched, nondiabetic controls were used to gather parameters in surgically and DT-untreated normal
mice (normal group).
(B) Kaplan-Meier survival analyses were performed on DT-i.c.v.-leptin and DT-i.c.v.-placebo mice. Statistical analyses were done using the Gehan-
Breslow-Wilcoxon test. ***p < 0.001 versus DT-i.c.v.-placebo mice. The number of mice at day 0 of DT-i.c.v.-leptin and DT-i.c.v.-placebo was 8 and 6,
respectively.
(legend continued on next page)
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Hypothalamic Pathway Enabling Life without Insulinexerts lipolytic actions but does not cause hypoglycemia (Fuji-
kawa et al., 2010; Wang et al., 2010; Yu et al., 2008). Thus, ex-
ploiting the slow-acting glycemia-lowering effect of leptin and/
or harnessing the component(s) underlying its effect may repre-
sent attractive alternative(s) or adjuvant(s) to insulin therapy.
In mammals able to produce insulin, the glycemia-lowering
action of leptin is mediated by its direct action on its cognate
receptors expressed by hypothalamic neurons. For example,
unilateral restoration of leptin receptors (LEPRs) signaling only
in the hypothalamic arcuate nucleus (ARC) normalizes hypergly-
cemia in mice otherwise deficient in LEPR signaling (Coppari
et al., 2005; Morton et al., 2005). Mechanistically, this action
seems to require intact hypothalamic phosphatidylinositol
3-kinase (PI3K) signaling because delivery of PI3K inhibitors
directly to the ARC impairs the ability of leptin to suppress hyper-
glycemia in these diabetic rodents (Morton et al., 2005).
Recently, the biochemical identity of the ARC neurons underly-
ing these actions of leptin has been unraveled. Indeed,
re-expression of LEPRs only in pro-opiomelanocortin (POMC)
neurons has been shown to be sufficient to restore normo-
glycemia in mice otherwise deficient in LEPR signaling (Berglund
et al., 2012; Huo et al., 2009). LEPRs in the ventromedial
hypothalamic nucleus (VMH) are also thought to be important
for mediating the glucoregulatory actions of leptin. In fact, micro-
injection of leptin into the VMH of lean mice increases glucose
uptake in skeletal muscle, heart, and interscapular brown adi-
pose tissue (iBAT) (Haque et al., 1999; Minokoshi et al., 1999).
Together, these results support the notion that in animals able
to produce insulin, the glycemia-lowering action of leptin is
mainly mediated by ARC and VMH neurons.
Because activation of either LEPRs or insulin receptor
signaling partly impinges on the same molecules (e.g., PI3K)
(Fukuda et al., 2008; Hill et al., 2008), and leptin enhances insulin
sensitivity in insulin-resistant rodents and humans (German
et al., 2009; Oral et al., 2002; Shimomura et al., 1999), the glyce-
mia-lowering effects of leptin have been thought to be due to
synergistic actions between administered leptin and endoge-
nously secreted insulin. However, in insulin-deficient rodents,
leptin administration is also very effective in ameliorating dia-
betes (Fujikawa et al., 2010; Wang et al., 2010; Yu et al., 2008).
These latter findings may represent the groundwork for devel-
oping improved therapies for diseases of insulin deficiency. To
reach this goal, a comprehensive understanding of the mecha-
nisms (molecules and cell types) underlying the lifesaving and
metabolic-improving actions of leptin in insulin deficiency is
needed.
In this study, we used two different models of insulin defi-
ciency: the streptozotocin (STZ)-induced (Fujikawa et al., 2010)
and the diphtheria toxin (DT)-induced b cell depleted models
(Thorel et al., 2010). By determining the metabolic outcomes of
i.c.v. leptin administration in these insulin-deficient models lack-
ing or re-expressing LEPRs only in select hypothalamic neurons,
we established the identity of (i) the neuronal populations and (ii)(C–H) Glucose levels in the blood, body weight, and food intake (C); glucagon in t
liver (F); insulin levels in the plasma andwhole pancreas (G); and representative dis
DT-i.c.v.-placebo, DT-i.c.v.-leptin, and normal mice (H). Statistical analyses wer
mean ± SEM (n = 4–6). ***p < 0.001, **p < 0.01, *p < 0.05 versus DT-i.c.v.-placebo
Figure S1.
Cell Meperipheral components underlying the lifesaving and metabolic-
improving actions of leptin in the context of insulin deficiency.
RESULTS
Brain LEPRs Mediate the Lifesaving and Metabolic
Actions of Leptin in Insulin Deficiency
Experimental evidence suggests that LEPRs expressed by
neurons within the central nervous system (CNS) underlie the
beneficial effect of leptin administration in the context of insulin
deficiency. First, the glucoregulatory actions of leptin are not
mediated by hepatic LEPRs, as insulin-deficient mice lacking
LEPRs only in liver respond normally to the hyperglycemia-
lowering action of leptin administration (Denroche et al., 2011).
Second, the idea that direct action of leptin on glucagon-
secreting a cells underlies the anti-T1DM action of leptin seems
to be at odds with our data indicating that pancreatic a cells do
not express LEPR-B (the receptor isoform that mediates the
majority of the biological actions of leptin) (Figures S1A–S1D
available online). Third, we have previously reported that i.c.v.
delivery of leptin permits survival and normalizes hyperglycemia
of STZ-induced insulin-deficient mice (Fujikawa et al., 2010).
However, STZ-treated mice retain minuscule amount of pancre-
atic insulin; therefore, it is unclear whether the residual insulin is
required for the beneficial effect induced by leptin treatment
(Fujikawa et al., 2010).
To address this issue, we used genetically engineered mice
that can be rendered completely insulin deficient. RIP-DTR
mice bear a rat insulin promoter (RIP)-DT receptor (DTR) allele
cloned into the Hprt locus of the X chromosome. Three indepen-
dent intraperitoneal (i.p.) DT administrations (at the dose of
0.5 mg/Kg of body weight each) in RIP-DTR mice have been
shown to ablate virtually all insulin-producing pancreatic b cells
(Thorel et al., 2010). Insulin deficiency in RIP-DTR mice was
achieved by following the established protocol in Thorel et al.
(2010) with a slight modification (Figure 1A). Accordingly, nearly
all pancreatic b cells were ablated in DT-injected RIP-DTR mice
(Figures S1E–S1G). Compared to normal mice, all DT-injected
RIP-DTR mice that underwent i.c.v.-placebo treatment (DT-
i.c.v.-placebo) displayed overtly high hyperglycemia, reduced
body weight, hyperphagia, and hyperglucagonemia and inevi-
tably succumbed within 15 days after the first DT administration
(Figures 1B, 1C, and 1D). However, the vast majority of DT-
injected RIP-DTR mice that underwent i.c.v. leptin treatment
(DT-i.c.v.-leptin) were viable and had significantly improved
hyperglycemia, hyperphagia, and hyperglucagonemia, albeit
their body weight remained similar to DT-i.c.v.-placebo mice
(Figures 1B, 1C, and 1D). In accordancewith improved hyperglu-
cagonemia, DT-i.c.v.-leptin mice had a hepatic level of phos-
phorylated cyclic AMP (cAMP) response element binding protein
(pCREB; an established readout of glucagon receptor signaling)
that was greatly reduced and indistinguishable compared to that
of DT-i.c.v.-placebo and normal mice, respectively (Figure 1E).he plasma (D); hepatic protein levels of pCREB and PEPCK (E); glycogen in the
tribution of cells expressing insulin (green) and glucagon (red) in the pancreas of
e done using one-way ANOVA (Tukey’s multiple comparison test). Values are
mice. ND, below the threshold of detection. Scale bar size = 100 mm. See also
tabolism 18, 431–444, September 3, 2013 ª2013 Elsevier Inc. 433
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Hypothalamic Pathway Enabling Life without InsulinHepatic phosphoenolpyruvate carboxykinase (PEPCK) protein
expression levels were improved, but not completely normal-
ized, by i.c.v. leptin administration (Figure 1E), and in line with
our previous report (Fujikawa et al., 2010), hepatic glycogen
levels were not improved by i.c.v. leptin administration (Fig-
ure 1F). Importantly, circulating and pancreatic insulin levels
were virtually abolished in both DT-i.c.v.-placebo and DT-
i.c.v.-leptin mice compared to normal mice (Figure 1G). Also,
immunohistological assays revealed a minimal presence of
pancreatic b cells in both DT-i.c.v.-placebo and DT-i.c.v.-leptin
mice compared to the normal group (Figure 1H). These data
suggest that the aforementioned effects of i.c.v. leptin adminis-
tration are not secondary to pancreatic b cell regeneration.
Collectively, our results establish that leptin administration per-
mits survival and improves hyperglycemia of mice totally lacking
insulin via CNS-dependent mechanisms.
Marginal Contribution of POMCLEPRs to the Actions of
Leptin in Insulin Deficiency
To determine the identity of the neuronal population(s) mediating
the effect of leptin in insulin deficiency, we used genetically
engineered mice that enabled the deletion of LEPRs in a
neuron-type-specific fashion. Because hypothalamic POMC
and steroidogenic factor 1 (SF1) neurons have been shown to
regulate glucose metabolism in insulin-intact mammals (Ber-
glund et al., 2012; Huo et al., 2009; Ramadori et al., 2011), we
directly tested whether LEPRs in POMC or SF1 neurons
(POMCLEPRs or SF1LEPRs, respectively) are required for the
effects of leptin in the context of insulin deficiency. Notably,
SF1 is encoded by the Nr5a1 gene, which is only expressed in
the VMH within the CNS (Choi et al., 2013). Thus, SF1 neurons
are a representative neuronal population of the VMH (Dhillon
et al., 2006). By breeding Pomc-Cre or Sf1-Cre allele to Leprflox
allele, we obtained LEPR-intact control (Leprflox/flox mice) and
Pomc-Cre;Leprflox/flox or Sf1-Cre;Leprflox/flox mice that lack
LEPRs only in POMC or SF1 neurons, respectively (Balthasar
et al., 2004; Dhillon et al., 2006). Insulin deficiency in Pomc-Cre;
Leprflox/flox, Sf1-Cre;Leprflox/flox, or Leprflox/flox mice wasFigure 2. LEPRs in POMC Neurons Are Required to Mediate a Margina
Deficiency
(A) Experimental design using streptozotocin (STZ)-treated mice (Fujikawa et al.,
LEPRs selectively in POMC neurons (Pomc-Cre;Leprflox/flox) or SF1 neurons (Sf1-
delivered i.c.v. to Pomc-Cre;Leprflox/flox, Sf1-Cre;Leprflox/flox, and Leprflox/flox mice
and STZ-Leprflox/flox-i.c.v.-leptin group, respectively). Placebo (PBS) was deliver
(B) Glucose levels in the blood, body weight, food intake, and insulin levels in the p
STZ-Pomc-Cre;Leprflox/flox-i.c.v.-leptin, and STZ-Leprflox/flox-i.c.v.-leptin mice.
(C) Kaplan-Meier survival analyses were performed on STZ-Leprflox/flox-i.c.v.-pla
mice. Statistical analyses were done using the log rank test (number of mice = 5),
STZ-Pomc-Cre;Leprflox/flox-i.c.v.-leptin, and STZ-Leprflox/flox-i.c.v.-leptin mice.
(D) glucagon levels in the plasma of STZ-Leprflox/flox-i.c.v.-placebo, STZ-Pomc-C
(E) Kaplan-Meier survival analyses were performed on DT-Leprflox/flox-i.c.v.-placeb
Statistical analyses were done using the log rank test (among all groups) followe
placebo). ***p < 0.001. The number ofmice at day 0 of DT-Leprflox/flox-i.c.v.-placeb
9, and 6, respectively. Glucose levels in the blood and food intake of the DT-Leprflo
i.c.v.-leptin mice.
(F) Glucagon levels in the DT-Leprflox/flox-i.c.v.-placebo, DT-Pomc-Cre;Leprflox/flo
date of death of succumbed DT-Leprflox/flox-i.c.v.-placebo mice and 25 days aft
Leprflox/flox-i.c.v.-leptin mice. Statistical analyses were done using one-way ANOV
3–9). ***p < 0.001, **p < 0.01 versus STZ- or DT-Leprflox/flox-i.c.v.-placebo or STZ-
versus STZ- or DT-Leprflox/flox-i.c.v.-leptin. ND, below the threshold of detection
Cell Meachieved by i.p. STZ administrations (Fujikawa et al., 2010) (Fig-
ure 2A). Compared to STZ-injected Leprflox/flox mice that under-
went i.c.v.-placebo treatment (STZ-Leprflox/flox-i.c.v.-placebo),
hyperglycemia was similarly reduced in STZ-injected Sf1-Cre;
Leprflox/flox mice that underwent i.c.v. leptin treatment (STZ-
Sf1-Cre;Leprflox/flox-i.c.v.-leptin) and STZ-injected Leprflox/flox
mice that underwent i.c.v. leptin treatment (STZ-Leprflox/flox-
i.c.v.-leptin) (Figure 2B). However, STZ-injected Pomc-Cre;
Leprflox/flox mice that underwent i.c.v. leptin treatment (STZ-
Pomc-Cre;Leprflox/flox-i.c.v.-leptin) displayed a blunted response
to the hyperglycemia-lowering action of the treatment (Fig-
ure 2B). Because food intake and body weight were comparable
between STZ-Pomc-Cre;Leprflox/flox-i.c.v.-leptin, STZ-Sf1-Cre;
Leprflox/flox-i.c.v.-leptin, and STZ-Leprflox/flox-i.c.v.-leptin mice,
the diminished action of leptin on hyperglycemia in the STZ-
Pomc-Cre;Leprflox/flox-i.c.v.-leptin group was not secondary to
hyperphagia (Figure 2B). Similarly, the dampened action of the
hormone was not due to impaired leptin delivery because phos-
phorylated signal transducer and activator of transcription 3
(pSTAT3; an established readout of leptin-induced LEPR sig-
naling) was readily detectable in the brain of STZ-Pomc-Cre;
Leprflox/flox-i.c.v.-leptin mice that displayed hyperglycemia (Fig-
ure S2). Notably, at 10 days after i.c.v. surgery, circulating insulin
was below the threshold of detection in all groups (Figure 2B),
suggesting that all of these mice were devoid of circulating
insulin.
As the hormonal effects on glycemia were slightly dampened,
we used a second cohort to assess whether the action of leptin
on survival was also altered in STZ-Pomc-Cre;Leprflox/flox-i.c.v.-
leptin mice. Similar to results obtained with the first cohort, food
intake and body weight were comparable between STZ-Pomc-
Cre;Leprflox/flox-i.c.v.-leptin and STZ-Leprflox/flox-i.c.v.-leptin
mice (Figure 2C and data not shown). Also, glycemia was again
moderately higher in the former group compared to the latter
(Figure 2C). Interestingly, no difference in the percentage of
survival between STZ-Pomc-Cre;Leprflox/flox-i.c.v.-leptin and
STZ-Leprflox/flox-i.c.v.-leptinmicewasnoted (Figure2C).Notably,
at 25 days into the treatment, circulating glucagon levels inl Component of Antidiabetic Action of Leptin in the Context of Insulin
2010). To induce insulin deficiency, STZ was i.p. administered to mice lacking
Cre;Leprflox/flox) and littermate control mice (Leprflox/flox). Leptin (25 ng/hr) was
(STZ-Pomc-Cre;Leprflox/flox-i.c.v.-leptin, STZ-Sf1-Cre;Leprflox/flox-i.c.v.-leptin,
ed i.c.v. to Leprflox/flox mice (STZ-Leprflox/flox-i.c.v.-placebo).
lasma of STZ-Leprflox/flox-i.c.v.-placebo, STZ-Sf1-Cre;Leprflox/flox-i.c.v.-leptin,
cebo, STZ-Pomc-Cre;Leprflox/flox-i.c.v.-leptin, and STZ-Leprflox/flox-i.c.v.-leptin
glucose levels in the blood, and food intake of STZ-Leprflox/flox-i.c.v.-placebo,
re;Leprflox/flox-i.c.v.-leptin and STZ-Leprflox/flox-i.c.v.-leptin mice.
o, DT-Pomc-Cre;Leprflox/flox-i.c.v.-leptin, and DT-Leprflox/flox-i.c.v.-leptinmice.
d by Gehan-Breslow-Wilcoxon test (each group versus DT-Leprflox/flox-i.c.v.-
o, DT-Pomc-Cre;Leprflox/flox-i.c.v.-leptin, andDT-Leprflox/flox-i.c.v.-leptin was 8,
x/flox-i.c.v.-placebo, DT-Pomc-Cre;Leprflox/flox-i.c.v.-leptin, and DT-Leprflox/flox-
x-i.c.v.-leptin, and DT-Leprflox/flox-i.c.v.-leptin mice. Harvested day means the
er i.c.v. leptin administration in DT-Pomc-Cre;Leprflox/flox-i.c.v.-leptin and DT-
A (Tukey’s or Dunnett’s multiple comparison test). Values are mean ± SEM (n =
or DT-Pomc-Cre;Leprflox/flox-i.c.v.-leptin mice. yyyp < 0.001, yyp < 0.01, yp < 0.05
. See also Figure S2.
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i.c.v.-leptin mice were similarly reduced compared to STZ-
Leprflox/flox-i.c.v.-placebo mice (Figure 2D).
To further assess the role of POMCLEPRs on the lifesaving and
hyperglycemia-lowering actions of leptin in the absence of
insulin, we used our DT model of insulin deficiency. By following
the breeding strategy described in the Supplemental Experi-
mental Procedures, the RIP-DTR allele was introduced into
mice lacking LEPRs only in POMC neurons and their controls.
Insulin deficiency in thesemicewas achievedby i.p. DT injections
as described above and shown in Figure 1A. Data presented in
Figure 2E indicate that i.c.v. leptin administration exerted similar
survival effects in DT-treated RIP-DTR mice lacking LEPRs only
in POMC neurons compared to their LEPR-intact controls. How-
ever, also in this model of insulin deficiency, i.c.v.-leptin-treated
mice lacking LEPRs in POMC neurons were slightly hyperglyce-
mic compared to i.c.v.-leptin-treated LEPR-intact controls (Fig-
ure 2E). Notably, circulating insulin was undetectable in all
groups (Figure 2F). In line with data in Figure 2D, POMCLEPRs
were dispensable for the effects of i.c.v. leptin administration
on glucagon also in the DT-induced model of insulin deficiency.
Indeed, at 25 days into the treatment, circulating glucagon levels
in DT-Pomc-Cre;Leprflox/flox-i.c.v.-leptin and DT-Leprflox/flox-
i.c.v.-leptin mice were indistinguishable (Figure 2G). Collectively,
our results from experiments conducted on two different mouse
models of insulin deficiency establish that POMCLEPRs are (i)
required for mediating only a marginal component of the hyper-
glycemia-lowering effect and (ii) dispensable for the lifesaving,
hyperphagia-suppressing, and hyperglucagonemia-lowering
actions of leptin in the context of insulin deficiency.
POMCLEPRs Are Not Sufficient for Mediating the Actions
of Leptin in Insulin Deficiency
Although our data shown in Figure 2 indicate that POMCLEPRs are
marginally important, these data do not establish whether
POMCLEPRs are sufficient to mediate the anti-T1DM effects of
leptin. To directly test this hypothesis, mice expressing LEPRs
only in POMC neurons were generated. The Pomc-Cre allele
was bred to a Cre-conditional Lepr null reactivatable (LeprTB)
allele that allows for the re-expression of endogenous LEPRs
upon Cre-mediated excision of a loxP-flanked transcriptional
blocking cassette (Berglund et al., 2012). Importantly, Pomc-
Cre;LeprTB/TB mice express LEPRs only in POMC neurons (Ber-
glund et al., 2012). By following the breeding strategy described
in the Supplemental Experimental Procedures, the RIP-DTR
allele was introduced into Pomc-Cre;LeprTB/TB mice and their
controls. Insulin deficiency in these mice was achieved by i.p.
DT injections as described above and in Figure 1A. In agreement
with data presented in Figures 1B and 1C, i.c.v. leptin administra-
tion reversed mortality and improved hyperglycemia in the vast
majority of DT-injected RIP-DTR mice (DT-i.c.v.-leptin) (Figures
3A and 3B). However, it failed to do so in DT-injected RIP-DTR
mice expressing LEPRs only in POMC neurons (DT-Pomc-Cre;
LeprTB/TB-i.c.v.-leptin) and DT-injected RIP-DTR mice deficient
in LEPRs (DT-LeprTB/TB-i.c.v.-leptin), both of which had similar
body weights (Figures 3A and 3B). Notably, the recalcitrant
response to treatment displayed by DT-LeprTB/TB-i.c.v.-leptin
and DT-Pomc-Cre;LeprTB/TB-i.c.v.-leptin mice occurred in the
presence of aminuscule amount of circulating insulin (Figure 3B).436 Cell Metabolism 18, 431–444, September 3, 2013 ª2013 ElsevieAlso, while i.c.v. leptin administration induced pSTAT3 in several
hypothalamic sites (including ARC and VMH) of DT-i.c.v.-leptin
mice, it failed to exert this action in DT-LeprTB/TB-i.c.v.-leptin
mice (Figure 3C), hence proving that the latter are indeed
LEPR-deficient mice. Furthermore, pSTAT3 was detected only
in ARC (the site at which POMC neurons are located) of DT-
Pomc-Cre;LeprTB/TB-i.c.v.-leptin mice (Figure 3C). These results
further bolster the idea that these mutants express functional
LEPRs only in POMC neurons (Berglund et al., 2012).
The refractory response to leptin administration displayed by
DT-Pomc-Cre;LeprTB/TB-i.c.v.-leptin mice could be due to
(i) failure to deliver the hormone into the brain of these mice,
(ii) DT injections causing ablation of POMC neurons, and/or
(iii) non-POMC neurons, which are crucial components of this
neurocircuitry. The first possibility is ruled out by data showing
pSTAT3 staining in ARC of DT-Pomc-Cre;LeprTB/TB-i.c.v.-leptin
mice (Figure 3C). The likelihood thatDT injections causedablation
of POMC neurons is also ruled out because hypothalamic Pomc
messenger RNA (mRNA) levels in RIP-DTR mice did not change
24 hr after DT injection, whereas the pancreatic preproinsulin
mRNA level drastically decreased in these mice at the same
time point (Figures S3A and S3B). As expected, glucose levels
in the blood increased 48 hr after DT injection (Figure S3C).
Also, the anatomical distribution of b-endorphin (a product of
POMC) in the hypothalamus was comparable between RIP-
DTR mice treated with or without DT (Figures S3D–S3I). On the
other hand, the anatomical distribution of pancreatic b cells was
dramatically different between these two groups (Figures S3D–
S3I). The possibility that DT injections caused ablation of non-
POMCneurons that are crucial components of this neurocircuitry
is also unlikely. In fact, our previously published results (Fujikawa
et al., 2010) and our data in Figure 1 strongly indicate that i.c.v.
leptin administration exerts very similar survival and antidiabetic
effects in theDT-inducedandSTZ-inducedmodels of insulin defi-
ciency. Nevertheless, Dtr was detected in pancreas and hypo-
thalamus of RIP-DTR mice (Figure S3J). Thus, we cannot rule
out the possibility that DT injections ablated other types of cells
within this brain structure. Taken together, our results indicate
that even if DT administration killed some hypothalamic cells in
mice bearing theRIP-DTRallele, these cells are likely dispensable
for mediating the beneficial effects of leptin administration.
Collectively, our results in Figures 2, 3, S2, and S3 establish
that POMCLEPRs exert only aminor role inmediating thebeneficial
effects of leptin administration in the context of insulin deficiency.
Importance of Concomitant Expression of LEPRs in
GABAergic and POMC Neurons
Todetermine the identity of the important neurons in the neurocir-
cuitry engaged by leptin, we took advantage of several lines of
evidence. First, our data in Figure 2 excluded a role for LEPRs
expressed by SF1 neurons that represent a large population of
leptin-responsive glutamatergic neurons (Vong et al., 2011). Sec-
ond, our data in Figures 2, 3, S2, and S3 establish that LEPRs on
POMCneurons (also in part glutamatergic) (Vonget al., 2011) play
only amarginal role inmediating the effects of leptin in insulin defi-
ciency. Thus, LEPRs on glutamatergic neurons are unlikely to
exert a major function in this pathway. Therefore, we investigated
the role of LEPRs expressed by GABAergic neurons. To directly
test the possibility that LEPRs on GABAergic neurons are ther Inc.
BA
Ha
rve
ste
d 
da
y
pS
TA
T3
-1 
da
y
5 d
ay
s
VMH
ARC
DT-LeprTB/TB-i.c.v.-leptin
DT-Pomc-Cre;LeprTB/TB-i.c.v.-leptin
DT-i.c.v.-leptin
DT-LeprTB/TB-i.c.v.-leptin
DT-Pomc-Cre;LeprTB/TB-i.c.v.-leptin
DT-i.c.v.-leptin
DT-i.c.v.-leptinDT-Pomc-Cre;
LeprTB/TB-i.c.v.-leptin
DT-LeprTB/TB
-i.c.v.-leptin
C
Ha
rve
ste
d 
da
y-1
 da
y
5 d
ay
s
Ha
rve
ste
d 
da
y-1
 da
y0 5 10 15 20 25
0
20
40
60
80
100
***
Days relative to surgery
Pe
rc
en
ts
ur
vi
va
l(
%
)
0
200
400
600
800
***** ***
G
lu
co
se
(m
g/
dL
)
0
20
40
60
******
***
B
od
y
w
ei
gh
t(
g)
0
5
10
15
ND
***In
su
lin
(n
g/
m
L)
Figure 3. LEPRs in POMC Neurons Are Not Sufficient to Mediate the Antidiabetic Action of Leptin in the Context of Insulin Deficiency
(A) Kaplan-Meier survival analyses were performed on insulin-deficient mice expressing LEPRs selectively in POMC neurons, LEPR-intact control (Lepr+/+ and
Pomc-Cre;Lepr+/+), and LEPR null littermates that received i.c.v. leptin (25 ng/hr) administration (DT-Pomc-Cre;LeprTB/TB-i.c.v.-leptin, DT-i.c.v.-leptin, DT-
LeprTB/TB-i.c.v.-leptin mice, respectively). Statistical analyses were done using the log rank test (among all groups) followed by the Gehan-Breslow-Wilcoxon test
(each group versus DT-LeprTB/TB-i.c.v.-leptin). ***p < 0.001. The number of mice at day 0 of DT-LeprTB/TB-i.c.v.-leptin, DT-Pomc-Cre;LeprTB/TB-i.c.v.-leptin, and
DT-i.c.v.-leptin was 11, 8, and 5, respectively.
(B and C) Glucose levels in the blood, body weight, and insulin levels in the plasma (B) and representative distribution of cells expressing phosphorylated STAT3
(pSTAT3) in themediobasal hypothalamus of DT-LeprTB/TB-i.c.v.-leptin, DT-Pomc-Cre;LeprTB/TB-i.c.v.-leptin, and DT-i.c.v.-leptin mice (C). Harvested daymeans
the date of death for succumbed DT-Pomc-Cre;LeprTB/TB-i.c.v.-leptin and DT-i.c.v.-leptin mice and 25 days after i.c.v. leptin administration for DT-i.c.v.-leptin
mice. Statistical analyses were done using one-way ANOVA (Tukey’s multiple comparison test). Values are mean ± SEM (n = 5–11). ***p < 0.001, **p < 0.01 versus
DT-LeprTB/TB-i.c.v.-leptin. ND, below the threshold of detection. Scale bar size = 100 mm. ARC, arcuate nucleus; VMH, ventromedial hypothalamic nucleus. See
also Figure S3.
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Hypothalamic Pathway Enabling Life without Insulincrucial mediators of the effects of leptin in insulin deficiency, we
assessed the consequence of i.c.v. leptin administration in insu-
lin-deficient mice expressing LEPRs only in GABAergic neurons.
The vesicular GABA transporter (VGAT) is encoded by the gene
Slc32a1 and biochemically characterizes GABAergic neurons.
By breeding the Vgat-ires-Cre allele (known to drive Cre-
mediated recombination of loxP-flanked alleles in all GABAergic
neurons) (Vong et al., 2011) to the LeprTB allele mice expressing
LEPRs only in GABAergic neurons (Vgat-ires-Cre;LeprTB/TBmice)
were obtained. By following the breeding strategy described in
the Supplemental Experimental Procedures, the RIP-DTR allele
was introduced into Vgat-ires-Cre;LeprTB/TB mice and their con-
trols. Insulin deficiency in these mice was achieved by i.p. DT
injections as described above and shown in Figure 1A.
As expected, no DT-treated Vgat-ires-Cre;LeprTB/TB;RIP-DTR
mice undergoing i.c.v. placebo administration (DT-VGAT-i.c.v.-
placebo) survived for longer than 10 days into treatment
(Figure 4A). In line with our results in Figure 1, 7 out of 8 DT-
i.c.v.-leptin controls survived 25 days into treatment (Figure 4A).
Notably, 5 out of 12 DT-treated Vgat-ires-Cre;LeprTB/TB;RIP-
DTR mice undergoing i.c.v. leptin administration (DT-VGAT-
i.c.v.-leptin) also survived 25 days into treatment (Figure 4A).Cell MeRemarkably, all of these survivors displayed significant hypergly-
cemic improvements, albeit these were not as complete as the
ones shown by DT-i.c.v.-leptin controls that have intact LEPRs
(Figure 4B). Insulin in the plasma was undetectable in both DT-
VGAT-i.c.v.-leptin survivors and DT-i.c.v.-leptin controls, hence
supporting the notion that DT-VGAT-i.c.v.-leptin survivors were
truly insulin deficient (data not shown). Food intake was also
similar between DT-VGAT-i.c.v.-leptin survivors and DT-i.c.v.-
leptin controls, while body weight tended to be slightly higher
in the former compared to the latter group (Figures 4B and 4C).
Interestingly, the ability of i.c.v. leptin administration to suppress
hyperglucagonemia was fully intact and only partial in DT-VGAT-
i.c.v.-leptin survivors and nonsurvivors, respectively, compared
to DT-i.c.v.-leptin controls (Figure 4D).
Notably, leptin-responsive GABAergic neurons are localized
only in ARC, lateral hypothalamic area (LHA), and dorsomedial
hypothalamus (DMH) within the CNS (Vong et al., 2011). Accord-
ingly, robust pSTAT3 staining was detected in the ARC, LHA,
and DMH of DT-VGAT-i.c.v.-leptin, but not in DT-VGAT-i.c.v.-
placebo, mice (Figure 4E). The different intragroup survival
outcomes and metabolic profiles displayed by DT-VGAT-i.c.v.-
leptin mice could be due to (i) failure to deliver the hormonetabolism 18, 431–444, September 3, 2013 ª2013 Elsevier Inc. 437
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Hypothalamic Pathway Enabling Life without Insulininto the brain, (ii) altered leptin sensitivity of DT-VGAT-i.c.v.-
leptin nonsurvivors, and/or (iii) DT injections ablating a significant
proportion of leptin-responsive VGAT-expressing neurons in DT-
VGAT-i.c.v.-leptin nonsurvivors. The aforementioned possibil-
ities are unlikely because the anatomical distribution of brain
pSTAT3 was comparable between DT-VGAT-i.c.v.-leptin survi-
vors and nonsurvivors (Figures S4A–S4F).
Thus, LEPRs on other non-GABAergic neuronal group(s) must
play a required role. Because our results in Figure 2 indicated
that POMCLEPRs are required, we investigated whether re-
expression of LEPRs in GABAergic and POMC neurons restores
a full responsiveness to leptin administration. By following the
breeding strategy described in the Supplemental Experimental
Procedures, mice expressing LEPRs selectively in GABAergic
and POMC neurons (Vgat-ires-Cre;Pomc-Cre;LeprTB/TB;RIP-
DTR mice) were obtained. Insulin deficiency in these mice was
achieved by i.p. DT injections as described above and shown
in Figure 1A. Re-expression of LEPRs in GABAergic and
POMC neurons had greater effects in mediating the lifesaving
and hyperglycemia-improving action of leptin administration
compared to re-expression of LEPRs only in GABAergic neurons
(Figures 5A and 5B). In fact, DT-VGAT-i.c.v.-leptin mice again
displayed a partial improvement in lethality and hyperglycemia,
while these parameters were similarly rescued in i.c.v.-leptin-
treated insulin-deficient mice expressing LEPRs concomitantly
only in GABAergic and POMC neurons (DT-VGAT-POMC-
i.c.v.-leptin group) compared to DT-i.c.v.-leptin controls (Figures
5A and 5B). In line with data shown in Figure 4D, DT-VGAT-i.c.v.-
leptin survivors were again found to display similar levels of
circulating glucagon compared to DT-i.c.v.-leptin controls (Fig-
ure 5C). Also, DT-VGAT-POMC-i.c.v.-leptin mice had circulating
glucagon levels indistinguishable from DT-VGAT-i.c.v.-leptin
survivors and DT-i.c.v.-leptin controls (Figure 5C). At 25 days af-
ter induction of insulin deficiency, insulin in the plasma was un-
detectable in all groups (data not shown).
Altogether, our results demonstrate that concomitant expres-
sion of LEPRs only in GABAergic and POMC neurons is sufficient
to fully mediate the lifesaving and antidiabetic effects of leptin
administration in the context of insulin deficiency and that the
vastmajorityof theseactionsareviaLEPRs inGABAergicneurons.
Improved Liver, Soleus, and iBAT Metabolism Underlie
the Actions of Leptin in Insulin Deficiency
To gather further insights into the mechanisms underpinning the
leptin-dependent pathway enabling life without insulin, we inter-Figure 4. LEPRs in GABAergic Neurons Are Sufficient to Largely Med
Insulin Deficiency
(A) Kaplan-Meier survival analyses were performed on DT-treated mice expressin
administration (DT-VGAT-i.c.v.-leptin) or placebo (PBS) administration (DT
Cre;Lepr+/+;RIP-DTR and Lepr+/+;RIP-DTR mice) littermate mice that received i.c
the log rank test (among all groups) followed by the Gehan-Breslow-Wilcoxon t
number of mice at day 0 of DT-VGAT-i.c.v.-placebo, DT-VGAT-i.c.v.-leptin, and
(B–D) Glucose levels in the blood and body weight (B), food intake (C), and gluca
(nonsurvivors), DT-VGAT-i.c.v.-leptin (survivors), and DT-i.c.v.-leptin mice.
(E) Representative distribution of cells expressing phosphorylated STAT3 (a re
hypothalamic arcuate nucleus (ARC), and dorsomedial nucleus (DMH) of DT-VGA
locations of LHA, ARC, and DMH are shown in red, dashed-line boxes (Frankli
(Dunnett’s multiple comparison test). Values are mean ± SEM (n = 3–12). Scale b
also Figure S4.
Cell Merogated the role of b-adrenergic receptors. These receptors have
been previously indicated as important components of the hypo-
thalamic-dependent pathway governing glucose metabolism
(Haque et al., 1999; Minokoshi et al., 1999). Thus, to directly
test whether b-adrenergic receptors are downstream effectors
of the neurocircuitry engaged by leptin, we assessed the meta-
bolic outcomes of i.c.v. leptin administration in mice devoid of
the three known b-adrenergic receptors (b-less mice) (Bachman
et al., 2002). As shown in Figure 6A, i.c.v. leptin administration
rescued hyperglycemia to similar extents in STZ-treated wild-
type (STZ-wild-type-i.c.v.-leptin) and b-less (STZ-b-less-i.c.v.-
leptin) mice. These genetic results were further corroborated
by pharmacological data. Indeed, administration of the b-adren-
ergic receptor blocker timolol did not alter the antidiabetic
actions of i.c.v. leptin administration in STZ-treated wild-type
mice (Figures 6B and 6C). Collectively, these data indicate that
b-adrenergic receptors are dispensable for the antidiabetic
action of leptin in the context of insulin deficiency.
We and others have reported that the improved hyperglycemia
engendered by leptin administration to insulin-deficient rodents
is not the result of increased glucose excretion (Fujikawa et al.,
2010; Wang et al., 2010; Yu et al., 2008). To determine the fate
of glucose in insulin-deficient mice undergoing leptin administra-
tion, we used glucose-tracing analyses (Figure 6D). Our results
indicate that i.c.v. leptin administration does not affect glucose
uptake in the brain or gastrocnemius and vastus skeletal muscle,
while it significantly enhances glucose uptake in soleus muscle
and iBAT of DT-treated RIP-DTR mice (Figure 6E). To further
elucidate the peripheral effects of i.c.v. leptin administration in
insulin-deficient mice, hepatic gene expression and metabolite
levels in STZ-Leprflox/flox-i.c.v.-leptin and STZ-Leprflox/flox-i.c.v.-
placebo mice (same animals as shown in Figure 2B) were
assessed by transcriptomics andmetabolomics assays, respec-
tively. The transcriptomics analysis revealed that more than 800
genes were significantly (p < 0.001) down- or upregulated by
i.c.v. leptin administration (Figure S5A). The metabolomics anal-
ysis indicated that 23 metabolites were significantly (p < 0.01)
altered by i.c.v. leptin administration (Figure S5B and Table
S1). Notably, pathway analysis indicated that several metabolic
pathways, including those relevant to glucose metabolism,
were significantly altered (p < 0.001) by i.c.v. leptin administra-
tion (Figure S5C and Table S2). We particularly focused on
glucose and glycogen metabolism because lower circulating
glucagon levels brought on by i.c.v. leptin administration may
affect those pathways. In line with our results that hepaticiate the Survival and Antidiabetic Action of Leptin in the Context of
g LEPRs selectively in GABAergic neurons that received i.c.v. leptin (25 ng/hr)
-VGAT-i.c.v.-placebo) and LEPR-intact control (composed of Vgat-ires-
.v. leptin administration (DT-i.c.v.-leptin). Statistical analyses were done using
est (compared each group versus DT-VGAT-i.c.v.-placebo). ***p < 0.001. The
DT-i.c.v.-leptin was 5, 12, and 8, respectively.
gon levels in the plasma (D) in DT-VGAT-i.c.v.-placebo, DT-VGAT-i.c.v.-leptin
adout of leptin-responsive neurons) in the lateral hypothalamic area (LHA),
T-i.c.v.-placebo, DT-VGAT-i.c.v.-leptin, and DT-i.c.v.-leptin mice. Anatomical
n and Paxinos, 2008). Statistical analyses were done using one-way ANOVA
ar size = 100 mm. yyyp < 0.001, yyp < 0.01, yp < 0.05 versus DT-i.c.v.-leptin. See
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Figure 5. LEPRs in GABAergic and POMC Neurons Are Sufficient to Fully Mediate the Antidiabetic Action of Leptin in the Context of Insulin
Deficiency
(A) Kaplan-Meier survival analyses were performed on DT-treated mice expressing LEPRs selectively in both GABAergic and POMC neurons (Vgat-ires-Cre;
Pomc-Cre;LeprTB/TB;RIP-DTR mice), GABAergic neurons (Vgat-ires-Cre;LeprTB/TB;RIP-DTR mice), and LEPR-intact control mice (composed of Vgat-ires-Cre;
Pomc-Cre;Lepr+/+;RIP-DTR, Vgat-ires-Cre;Lepr+/+;RIP-DTR, Pomc-Cre;Lepr+/+;RIP-DTR, and Lepr+/+;RIP-DTR mice) that received i.c.v. leptin (25 ng/hr)
administration (DT-VGAT-POMC-i.c.v.-leptin, DT-VGAT-i.c.v.-leptin, and DT-i.c.v.-leptin). Statistical analyses were done using the log rank test. The number of
mice at day 0 of DT-VGAT-i.c.v.-leptin, DT-VGAT-POMC-i.c.v.-leptin, and DT-i.c.v.-leptin was 8, 7, and 9, respectively.
(B and C) Glucose levels in the blood of DT-VGAT-i.c.v.-leptin (nonsurvivors), DT-VGAT-i.c.v.-leptin (survivors), VGAT-POMC-i.c.v.-leptin, and DT-i.c.v.-leptin (C)
and glucagon levels in the plasma in DT-VGAT-i.c.v.-leptin (survivors), DT-VGAT-POMC-i.c.v.-leptin, and DT-i.c.v.-leptin at 25 days (C). Statistical analyses were
done using one-way ANOVA (Dunnett’s multiple comparison test). Values are mean ± SEM (n = 3–9). yyp < 0.05, yp < 0.05 versus DT-i.c.v.-leptin.
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Hypothalamic Pathway Enabling Life without Insulinglycogen levels were not altered by i.c.v. leptin administration
(Figure 1F) (Fujikawa et al., 2010), we found many genes and
metabolites relevant to this pathway that were not significantly
altered by i.c.v. leptin administration (Figure S5D and Table
S2). On the other hand, hepatic glucose content and the expres-
sion of glyceraldehyde-3-phosphate dehydrogenase and phos-
phoglycerate kinase 1 (both of which encode for enzymes of
the glycolytic pathway) were reduced by i.c.v. leptin administra-
tion (Figure S5D). These results indicate that although not
normalized, the liver of i.c.v.-leptin-treated insulin-deficient
mice displayed improved metabolomics and transcriptomics
profiles compared to i.c.v.-placebo-treated insulin-deficient
mice. Collectively, our results suggest that increased glucose
uptake and utilization by soleus and iBAT and improved hepatic
metabolism are components of the mechanism underlying the
antidiabetic action of leptin in the context of insulin deficiency.
DISCUSSION
In this study, we unraveled a neurocircuitry whereby leptin
engages hypothalamic GABALEPRs and POMCLEPRs to permit
survival and maintain euglycemia in the context of complete in-
sulin deficiency. This conclusion was drawn mainly because
concomitant re-expression of LEPRs in GABAergic and POMC
neurons is sufficient to mediate virtually all of the lifesaving and
antidiabetic actions of leptin administration in insulin-deficient
mice (Figure 5). Our results also clarified the contribution that
each one of the two aforementioned neuronal populations exerts
on this pathway. As shown in Figure 2, the effects of i.c.v. leptin
administration on survival, food intake, and circulating glucagon
level do not require POMCLEPRs. Although our results indicate
that POMCLEPRs are required for mediating the effect on hyper-
glycemia, their contribution to this action is marginal. In fact,
data shown in Figure 2 indicate that the ability of i.c.v. leptin
administration to suppress hyperglycemia in the STZ- and DT-440 Cell Metabolism 18, 431–444, September 3, 2013 ª2013 Elsevieinduced models of insulin deficiency is only slightly diminished
in mutants lacking POMCLEPRs. Also, these receptors alone are
not sufficient for mediating any of the effects of i.c.v. leptin
administration in the context of insulin deficiency (Figure 3). On
the other hand, our data strongly suggest that LEPRs in
GABAergic neurons mediate a large component of the hormonal
effects on survival and glucose metabolism in the context of
complete insulin deficiency (Figure 4). Thus, the beneficial
effects of leptin administration in insulin-depleted mice are
largely mediated by direct action of the hormone leptin on
GABALEPRs, while only a minimal component of these effects is
mediated by POMCLEPRs.
Unger and colleagues have provided experimental support for
the idea that leptin improves diabetes of insulin-deficient rodents
in part via diminishing circulating glucagon content and action
(Lee et al., 2012; Wang et al., 2010; Yu et al., 2008). Our results
are in line with this notion. Indeed, in our leptin-treated insulin-
deficient mouse models displaying ameliorated hyperglycemia,
circulating glucagon level and action were also improved
(Figures 1F, 2D, 2G, 4D, and 5C). Combined with data shown
in Figures S1A–S1D indicating that LEPR-B is not expressed
by pancreatic a cells, our results suggest that the hyperglucago-
nemia-lowering effect of leptin is not via direct action of the
hormone on pancreatic a cells, but rather via indirect action
through hypothalamic GABAergic neurons. Further studies
will be needed to unravel all components of this GABAergic
neuron-pancreatic a cell axis.
Although GABAergic neurons are widely distributed
throughout the CNS, the subgroup of GABAergic neurons also
able to express LEPRs is restricted to in the ARC, DMH, and
LHA (Figure 4E); notably, these results are in line with previously
reported data (Vong et al., 2011). Therefore, the direct action of
leptin on one or several of the aforementioned three sites must
be important for the lifesaving and antidiabetic action of the
hormone in the context of insulin deficiency (Figure 4E). Amongr Inc.
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Figure 6. Leptin Administration Induces Glucose Uptake in Soleus and iBAT of Insulin-Deficient Mice
(A) Glucose level in the blood of insulin-deficient b-less mice (that do not express any types of b-adrenergic receptors) and their wild-type controls that received
i.c.v. leptin (25 ng/hr) administration (STZ-b-less-i.c.v.-leptin and STZ-wild-type-i.c.v.-leptin groups, respectively). Insulin deficiency was induced by adminis-
tration of STZ, as shown in Figure 2.
(B and C) Experimental design (B) and glucose level in the blood of STZ-treated Friend virus B (FBV)/NIH Jackson (NJ) mice that received i.c.v. administration of
leptin (25 ng/hr) followed by administrations of b-adrenergic receptor blocker timolol (1 mg/kg BW) or placebo (0.9% saline solution) (C). Mice were injected i.p.
twice a day from day 7 up to day 9 and once more at 2 hr before sacrifice.
(D) Experimental design of assessment of basal glucose utilization. The experiment was carried out 10 days after i.c.v. administration, as described in Figure 1A.
(E) Glucose utilization levels in soleus muscle, gastrocnemius muscle, vastus muscle, interscapular brown adipose tissue and brain of DT-i.c.v.-leptin, DT-i.c.v.-
placebo, and normal mice. Values are mean ± SEM (n = 4–6). Statistical analyses were done using unpaired t test or one-way ANOVA (Tukey’s multiple
comparison test). *p < 0.05 versus DT-i.c.v.-placebo mice. See also Figure S5 and Tables S1 and S2.
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Hypothalamic Pathway Enabling Life without Insulinthe plausible candidates are agouti-related protein (AgRP)-
expressing neurons, as they are (i) located in the ARC, (ii)
GABAergic, and (iii) known to express LEPRs (Vianna and Cop-
pari, 2011). Thus, to directly test whether AgRP neurons are
indeed the crucial neurons in this neurocircuitry, assessing the
outcomes of leptin administration in insulin-deficient mice ex-
pressing LEPRs only in AgRP neurons appears to be the ideal
experimental approach. Such mutants can theoretically be
generated by breeding the LeprTB allele to the Agrp-ires-Cre
transgene (Tong et al., 2008). Nevertheless, our attempts to
achieve this goal failed, due to the nearly 100% frequency ofCell Medetectable Cre-recombined LeprTB allele in sites in which
AgRP neurons are not present in Agrp-ires-Cre;LeprTB/TB mice.
Tackling the relevance of LEPRs in DMH and/or LHA is currently
a technically difficult task mainly because of the lack of DMH-
and/or LHA-specific-Cre mouse lines. Thus, future studies
aimed at sorting out the contribution that LEPRs expressed by
GABAergic neurons within the ARC, DMH, and LHA on the
lifesaving and antidiabetic action of leptin in the context of insulin
deficiency are warranted.
It is of interest that while POMCLEPRs are sufficient to mediate
the effects of leptin on glucose metabolism in rodents able totabolism 18, 431–444, September 3, 2013 ª2013 Elsevier Inc. 441
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Hypothalamic Pathway Enabling Life without Insulinsecrete insulin (Berglund et al., 2012), they are not sufficient to
mediate these glucoregulatory effects of the hormone in rodents
devoid of insulin (Figure 3). These results demonstrate that insulin
is necessary for POMC neurons to trigger the cascade of events
that bring about reduced hyperglycemia induced by leptin. Along
these lines, in rodents able to produce insulin, hypothalamic-
mediated control of glucosemetabolism (as, for example, in skel-
etal muscle and iBAT) relies on the activation of sympathetic ner-
vous system (SNS) neurons (these cells secrete catecholamines
whose targets are adrenergic receptors) (Minokoshi et al., 1999;
Ramadori et al., 2011). However, our genetic and pharmacolog-
ical data in Figures 6A and 6C indicate that b-adrenergic recep-
tors are dispensable for hypothalamic-dependent glucoregula-
tory actions of leptin in rodents unable to produce insulin. It is
important to note that our results cannot rule out the possibility
that other types of adrenergic receptors (e.g., a-adrenergic
receptors) and/or receptors whose ligands secreted by SNS
neurons are not catecholamines are important components of
the aforementioned mechanism. Nevertheless, we suggest that
alternative non-SNS pathways are engaged by leptin to increase
glucose uptake in skeletal muscle and iBAT in the context of in-
sulin deficiency (Figure 6E). These pathways may include para-
sympathetic nervous system neurons and/or humoral factor(s),
and future studies will be needed to directly test this
hypothesis. Collectively, our data and previously published re-
sults mentioned above indicate that different pathways can be
engaged by hypothalamic neurons in order to keep glucose
metabolism in check in the presence versus absence of insulin.
From a therapeutic viewpoint, our results could pave the way
for developing the urgently needed improved therapies for the
millions of people affected by insulin deficiency (e.g., T1DM
and some T2DM patients) (Butler et al., 2007; Coppari and Bjør-
bæk, 2012; Talchai et al., 2012). In fact, the sole therapeutic avail-
able to these patients is insulin administration that, as discussed
in the Introduction, bears several limitations and can even under-
lie some of the serious morbidities seen in these patients (Larsen
et al., 2002; Orchard et al., 2003). Although these preclinical
results indicate that leptin therapy may represent an ideal alter-
native, its applicability in insulin-deficient humans seems
improbable. Indeed, several clinical trials failed to show effec-
tiveness of leptin administration in patients who are not severely
hypoleptinemic or totally lacking leptin; yet, the vast majority of
T2DM and insulin-treated T1DM subjects are not known to be
severely hypoleptinemic or leptin deficient (Coppari and Bjør-
bæk, 2012). Therefore, targeting the cellular and molecular com-
ponents underlying the effects of leptin in insulin deficiency may
prove efficacious in the clinical arena. Here, we identified crucial
components of this pathway; hence, we believe that our results
bear important clinical significance. In fact, harnessing hypotha-
lamic GABAergic and POMC neurocircuitry and/or its down-
stream effector components (e.g., brown adipocytes) may
permit survival and greatly improve hyperglycemia in people
suffering from diseases characterized by insulin deficiency.EXPERIMENTAL PROCEDURES
Animals
All mice were housed with standard chow diet and water available ad libitum in
a light- and temperature-controlled environment. We used male mice. Tail442 Cell Metabolism 18, 431–444, September 3, 2013 ª2013 ElsevieDNA was collected from each mouse to determine its genotype. Genotyping
primers are described in Table S3. Care of mice was within the Institutional
Animal Care and Use Committee (IACUC) guidelines, and all the procedures
were approved by the University of Texas Southwestern Medical Center
IACUC.
Induction of Insulin Deficiency byDiphtheria Toxin or Streptozotocin
Injection
We used 3- to 4-month-old male RIP-DTR mice whose body weights (BWs)
were approximately 30 g. Diphtheria toxin (Sigma) was dissolved in sterile
0.9% NaCl and i.p. administered into RIP-DTR mice to ablate pancreatic b
cells (0.5 mg/kg BW; on days 0, 3, and 5). Streptozotocin (Sigma) was dissolved
in cold-sterile 0.9% NaCl and immediately i.p. administered (150 mg/kg BW;
two times at one week intervals) into mice (Fujikawa et al., 2010).
i.c.v. Leptin Administration
Leptin (PeproTech; 25 ng/hr/0.11 mL) was chronically i.c.v. administered by the
osmotic pump (ALZET) as previously described (Fujikawa et al., 2010). A sterile
PBS (pH = 7.4; Invitrogen) solution was administered into the control group as
placebo treatment.
Assessment of Energy Substrates and Hormone Levels
Daily glycemia, plasma, and pancreatic insulin were measured as previously
described (Fujikawa et al., 2010). Plasma glucagon was measured as previ-
ously described (Berglund et al., 2012).
Assessment of mRNA and Protein Contents
mRNA levels and protein contents in the hypothalamus, pancreas, and liver
were determined by the previously described methods with slight modifica-
tions (Fujikawa et al., 2010).
Immunohistochemistry
Phosphorylation of STAT3 in the brain was determined as previously described
(Scott et al., 2009). Pancreatic glucagon and insulin distribution was deter-
mined as previously described (Fujikawa et al., 2010)
Assessment of Basal, Tissue-Specific Glucose Uptake
Mice were fasted for 1.5 hr and then i.p. injected with 150 uCi of
[2-14C]deoxyglucose. Samples to measure blood glucose and plasma
14C-specific activity were taken at t = 5 (preinjection), 5, 15, and 30 min.
Mice were then euthanized immediately after the final sample, and tissues
were quickly dissected and frozen in liquid nitrogen. Methods and calculations
to determine tissue-specific glucose uptake (Rg) have been previously
described (Fueger et al., 2003; Kraegen et al., 1985).
Statistical Analysis
With the exception of microarray and metabolomics results, all data sets were
analyzed for statistical significance using Prism (GraphPad) as indicated in
each of the figure legends. Error bars in all figures represent SEM.
ACCESSION NUMBERS
The microarray data were deposited to The National Center for Biotechnology
Information under the accession number GSE48598.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2013.08.004.
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